Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

252
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
252
Nonlinear Pharmacokinetics: Overview01:19

Nonlinear Pharmacokinetics: Overview

337
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
337
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

66
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
66
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

67
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
67
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

643
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
643
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

56
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
56
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Leveraging Pharmacokinetic Parameters As Covariate In Bayesian Logistic Regression Model To Optimize Dose Selection In Early Phase Oncology Trial.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Leveraging Pharmacokinetic Parameters As Covariate In Bayesian Logistic Regression Model To Optimize Dose Selection In Early Phase Oncology Trial.

Related Experiment Video

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
06:13

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Published on: February 21, 2020

6.6K

Leveraging pharmacokinetic parameters as covariate in Bayesian logistic regression model to optimize dose selection in early phase oncology trial.

Xin Wei1, Xiaosong Li1, Ziyan Guo1

  • 1Global Biometrics and Data Science, Bristol Myers Squibb, Madison, New Jersey, USA.

Journal of Biopharmaceutical Statistics
|July 19, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Optimizing early phase oncology drug development requires balancing safety and efficacy. This study enhances dose selection using bivariate Bayesian logistic regression (BLRM) with pharmacokinetic (PK) data, improving the identification of optimal doses for late-stage trials.

Keywords:
BLRM-EWOC (Bayesian logistic regression model with escalation with overdose control)BayesianDose optimizationPharmacokinetics (PK)

More Related Videos

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.1K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.6K

Related Experiment Videos

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
06:13

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Published on: February 21, 2020

6.6K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.1K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.6K

Area of Science:

  • Oncology Drug Development
  • Clinical Trial Design
  • Biostatistics

Background:

  • Early phase oncology trials are crucial for successful drug development.
  • Traditional dose-finding methods like 3+3 may not adequately balance safety and efficacy.
  • Bivariate Bayesian logistic regression (BLRM) improves dose selection accuracy based on dose-limiting toxicity (DLT).

Purpose of the Study:

  • To address challenges in optimizing dose selection in Phase I oncology trials.
  • To investigate the impact of pharmacokinetic (PK) variability on dose selection.
  • To propose methods for refining dose selection in escalation and expansion phases.

Main Methods:

  • Utilized a Phase I clinical trial dataset to demonstrate challenges.
  • Employed simulation studies to evaluate BLRM with PK covariates.
covariate
phase 1 oncology trial
  • Developed model- and rule-based methods for patient-level dose modification in expansion cohorts.

    • Main Results:

    • Fitting BLRM with dose-independent PK parameters as covariates improved the accuracy of identifying optimal dose levels based on DLT rates.
    • Proposed patient-level dose modification strategies based on PK parameters in expansion cohorts.
    • Simulations indicated a higher likelihood of advancing doses with manageable toxicity and efficacy.

    Conclusions:

    • Integrating PK data into BLRM models enhances dose selection accuracy in early oncology trials.
    • Patient-specific dose adjustments in expansion cohorts improve the probability of successful late-phase development.
    • This approach offers a more robust strategy for optimizing dose selection in early phase oncology drug development.